Literature DB >> 29750897

Involvement of FFA1 and FFA4 in the regulation of cellular functions during tumor progression in colon cancer cells.

Kaede Takahashi1, Kaori Fukushima1, Yuka Onishi1, Kanako Minami1, Shiho Otagaki1, Kaichi Ishimoto1, Nobuyuki Fukushima2, Kanya Honoki3, Toshifumi Tsujiuchi4.   

Abstract

Free fatty acid receptor 1 (FFA1) and FFA4 mediate a variety of biological responses through binding of medium- and long-chain free fatty acids. The aim of this study was to investigate an involvement of FFA1 and FFA4 in the regulation of cellular functions during tumor progression in colon cancer cells. The long-term fluorouracil (5-FU) and cisplatin (CDDP) treated cells were generated from DLD1 cells (DLD-5FU and DLD-CDDP cells, respectively). FFAR1 expressions were lower in DLD-5FU and DLD-CDDP cells than in DLD1 cells. In contrast, DLD-5FU and DLD-CDDP cells showed the high FFAR4 expressions, compared with DLD1 cells. The cell motile activities of DLD-5FU and DLD-CDDP cells were reduced by GW9508 which is an agonist of FFA1 and FFA4. Moreover, GW1100, an antagonist of FFA1, inhibited the cell motile activities of DLD-5FU and DLD-CDDP cells. To evaluate whether FFA1 and FFA4 regulate the enhancement of cell motility, invasion and colony formation, highly migratory (hmDLD1) cells were established from DLD1 cells. FFAR1 expression was significantly higher in hmDLD1 cells than in DLD1 cells, but no change of FFAR4 expression was observed. The elevated cell motile and invasive activities and colony formation of hmDLD1 cells were suppressed by FFA1 inhibition. These results suggest that FFA1 and FFA4 are involved in the regulation of cellular functions during tumor progression in colon cancer DLD1 cells.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cisplatin; Colon cancer cells; FFA1; FFA4; Fluorouracil

Mesh:

Substances:

Year:  2018        PMID: 29750897     DOI: 10.1016/j.yexcr.2018.05.005

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

1.  The key royal jelly component 10-hydroxy-2-decenoic acid protects against bone loss by inhibiting NF-κB signaling downstream of FFAR4.

Authors:  Yosuke Tsuchiya; Mikihito Hayashi; Katashi Nagamatsu; Takehito Ono; Masaki Kamakura; Takanori Iwata; Tomoki Nakashima
Journal:  J Biol Chem       Date:  2020-07-09       Impact factor: 5.157

2.  Serum Free Fatty Acids and G-Coupled Protein Receptors Are Associated With the Prognosis of Epithelial Ovarian Cancer.

Authors:  Lili Zhang; Xiangzhong Zhao; Huijun Chu; Han Zhao; Xiaoying Lai; Jing Li; Teng Lv
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

3.  GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery.

Authors:  Gabriele Carullo; Sarah Mazzotta; Margarita Vega-Holm; Fernando Iglesias-Guerra; José Manuel Vega-Pérez; Francesca Aiello; Antonella Brizzi
Journal:  J Med Chem       Date:  2021-04-10       Impact factor: 7.446

Review 4.  Development of Free Fatty Acid Receptor 4 (FFA4/GPR120) Agonists in Health Science.

Authors:  So-Eun Son; Nam-Jung Kim; Dong-Soon Im
Journal:  Biomol Ther (Seoul)       Date:  2021-01-01       Impact factor: 4.634

5.  The Regulatory Role of Neuropeptide Gene Glucagon in Colorectal Cancer: A Comprehensive Bioinformatic Analysis.

Authors:  Wenfeng Du; Yue Miao; Guoqing Zhang; Guangcai Luo; Peng Yang; Fei Chen; Benhua Zhang; Chenggang Yang; Gang Li; Jin Chang
Journal:  Dis Markers       Date:  2022-03-18       Impact factor: 3.434

6.  Label-free cell phenotypic study of FFA4 and FFA1 and discovery of novel agonists of FFA4 from natural products.

Authors:  Fangfang Xu; Han Zhou; Xiumei Liu; Xiuli Zhang; Zhiwei Wang; Tao Hou; Jixia Wang; Lala Qu; Pengyu Zhang; Hailong Piao; Xinmiao Liang
Journal:  RSC Adv       Date:  2019-05-15       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.